Cargando…

Current advances related to Clostridium difficile infection

Clostridium difficile infection (CDI) can trigger various responses, ranging from asymptomatic carriage to fulminant colitis. Hard-to-cure CDI, such as severe CDI, multiple recurrences of CDI, refractory CDI, and hypervirulent strains of C. difficile, require new treatments, although antibiotics suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yong Gil, Jang, Byung Ik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418153/
https://www.ncbi.nlm.nih.gov/pubmed/25900952
_version_ 1782369444247371776
author Kim, Yong Gil
Jang, Byung Ik
author_facet Kim, Yong Gil
Jang, Byung Ik
author_sort Kim, Yong Gil
collection PubMed
description Clostridium difficile infection (CDI) can trigger various responses, ranging from asymptomatic carriage to fulminant colitis. Hard-to-cure CDI, such as severe CDI, multiple recurrences of CDI, refractory CDI, and hypervirulent strains of C. difficile, require new treatments, although antibiotics such as metronidazole and vancomycin are the treatment of choice for initial and first relapsing CDI. Active immunization with C. difficile toxins and faecal microbiota transplantation deserve special attention. Here we describe these strategies for difficult-to-treat CDI.
format Online
Article
Text
id pubmed-4418153
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44181532015-05-12 Current advances related to Clostridium difficile infection Kim, Yong Gil Jang, Byung Ik Indian J Med Res Review Article Clostridium difficile infection (CDI) can trigger various responses, ranging from asymptomatic carriage to fulminant colitis. Hard-to-cure CDI, such as severe CDI, multiple recurrences of CDI, refractory CDI, and hypervirulent strains of C. difficile, require new treatments, although antibiotics such as metronidazole and vancomycin are the treatment of choice for initial and first relapsing CDI. Active immunization with C. difficile toxins and faecal microbiota transplantation deserve special attention. Here we describe these strategies for difficult-to-treat CDI. Medknow Publications & Media Pvt Ltd 2015-02 /pmc/articles/PMC4418153/ /pubmed/25900952 Text en Copyright: © Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kim, Yong Gil
Jang, Byung Ik
Current advances related to Clostridium difficile infection
title Current advances related to Clostridium difficile infection
title_full Current advances related to Clostridium difficile infection
title_fullStr Current advances related to Clostridium difficile infection
title_full_unstemmed Current advances related to Clostridium difficile infection
title_short Current advances related to Clostridium difficile infection
title_sort current advances related to clostridium difficile infection
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418153/
https://www.ncbi.nlm.nih.gov/pubmed/25900952
work_keys_str_mv AT kimyonggil currentadvancesrelatedtoclostridiumdifficileinfection
AT jangbyungik currentadvancesrelatedtoclostridiumdifficileinfection